Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 12/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | KIF5B | P33176 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | TEK | Q02763 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6030271 | 0.95 | KDM1A (0.51) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6101121 | 0.91 | KDM1A (0.53) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6031036 | 0.88 | KDM1A (0.56) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6031428 | 0.88 | KDR (0.53) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL1401666 | 0.88 | KDM1A (0.54) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6029734 | 0.86 | KDM1A (0.51) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL4373812 | 0.85 | KDM1A (0.64) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL4382606 | 0.84 | KDM1A (0.55) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6101329 | 0.84 | KDM1A (0.48) | KDM1APDGFRBKDREGFRLCK | |
| SCHEMBL6031295 | 0.83 | KDR (0.47) | KDM1APDGFRBKDREGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | claimed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | KDM1A 2417/4885PDGFRB 125/4885KDR 3/4885 |
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | KDM1A 2501/4885PDGFRB 160/4885KDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.